Atlas Trials

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

Clinical trial NCT02532257 · COMPLETED

Trial details

NCT number
NCT02532257
Sponsor
M.D. Anderson Cancer Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Ann Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage III Marginal Zone LymphomaAnn Arbor Stage IV Follicular LymphomaAnn Arbor Stage IV Marginal Zone LymphomaCD20 PositiveGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma
Start date
2016-04-11
Primary completion
2023-08-15
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.